Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure

CardioKine

Status and phase

Completed

Phase 2

Conditions

Congestive Heart Failure

Treatments

Drug: Placebo

Drug: Lixivaptan

Study type

Interventional

Funder types

Industry

Identifiers

NCT01055912

CK-LX2401

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of oral lixivaptan capsules in patients with congestive heart failure.

Full description

Diuretics are used extensively in the treatment of patients with CHF, and their efficacy is well established. However, there is a tendency for currently used diuretics to increase afterload and deplete electrolytes, and in many patients ventricular function continues to deteriorate over time.

Loop diuretics, such as furosemide, also have known negative effects on renal function reducing the glomerular filtration rate, and have been shown to activate the RAA system.

Lixivaptan is a potent, non-peptide selective antagonist of the vasopressin V2 receptor.

Lixivaptan treatment results in increased free water excretion, thus decreasing urine osmolality, increasing urine flow, and increasing serum osmolality. Short-term treatment with lixivaptan has demonstrated improved fluid management and electrolyte balance in HF patients.

This study was designed to assess the effects of vasopressin blockade with lixivaptan in patients with CHF with volume overload. A placebo-control arm will allow for assessment of the effect of lixivaptan in addition to standard diuretic therapy as compared with standard diuretic therapy alone.

Enrollment

170 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ability to understand the purpose and risks of the study and to provide signed and dated informed consent.
Men and women aged 18 years or older.
History of chronic CHF defined as requiring standard HF treatment (including diuretics) for a minimum of 30 days.
Documented LVEF by any method within 12 months prior to screening.
The patient has clinical evidence of volume overload at the time of inclusion with at least one of the following:
- Dyspnea
- Pulmonary congestion (rales)
- Peripheral edema
- Increased jugular venous pressure and/or hepatic congestion with ascites
- Chest x-ray consistent with CHF
- Plasma brain natriuretic peptide (BNP) ≥150 pg/mL or N-terminal prohormone brain natriuretic peptide (NT pro-BNP) ≥450 pg/mL

Exclusion criteria

Women who are pregnant (positive pregnancy test), breastfeeding, or who will not adhere to the reproductive precautions as outlined in this protocol and in the informed consent form (ICF).
Sustained (three blood pressure measurements over 1 hour) systolic blood pressure <90 mmHg at Screening or Day 0.
ST segment elevation myocardial infarction or stroke within 30 days prior to Screening.
Hemodynamically destabilizing cardiac arrhythmia within 30 days prior to Day 0.
Clinically significant valvular disease.
Known clinically significant obstructive, restrictive, or hypertrophic cardiomyopathy.
Cardiac surgery or percutaneous coronary intervention within 30 days prior to Day 0.
Major surgical procedure within 7 days prior to Day 0.
Likely to undergo cardiac transplantation, left ventricular assist device (LVAD) or other device implantation, or other cardiac surgery within 3 months after Screening.
Placement of implantable cardioverter defibrillator or cardiac resynchronization therapy device within 60 days prior to Day 0.
CHF due to uncorrected thyroid disease, active myocarditis, or known amyloid cardiomyopathy.
Presence of any clinically significant (as determined by the Investigator) endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, oncologic, and/or other major disease that might interfere with safe and compliant participation in this study.
Screening laboratory findings as follows:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal
- Total bilirubin >2.0 mg/dL
- Serum creatinine >3.0 mg/dL
- Hemoglobin <9.0 g/dL
Uncontrolled diabetes mellitus as defined by the Investigator (e.g., glycosylated hemoglobin [HbA1c] >9%).
History of chronic drug/medication abuse within the past 6 months; or current alcohol abuse.
Co-morbid condition with an expected survival of less than 3 months.
Known allergy to any vasopressin antagonist or any condition for which treatment with a vasopressin antagonist may present undue risk to the patient.
Current or recent administration (within 7 days of Day 0) of prohibited medications as listed in Section 8.6.4 .
Participation in any other investigational study of drugs or devices within 30 days prior to Screening.